

NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:47:25 ON 07 MAR 2006

=> file medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 10:47:38 ON 07 MAR 2006

FILE LAST UPDATED: 4 MAR 2006 (20060304/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s anti () PEG

616721 ANTI
6 ANTIS
616725 ANTI
(ANTI OR ANTIS)
9879 PEG
777 PEGS
10278 PEG

L1 (PEG OR PEGS)
7 ANTI (W) PEG

=> s l1 not py>2000

2953639 PY>2000
(PY>20009999)

L2 4 L1 NOT PY>2000

=> d ibib 1-4

L2 ANSWER 1 OF 4 MEDLINE on STN

ACCESSION NUMBER: 2000191525 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10725103
TITLE: Efficient clearance of poly(ethylene glycol)-modified
immunoenzyme with anti-PEG monoclonal
antibody for prodrug cancer therapy.
AUTHOR: Cheng T L; Chen B M; Chern J W; Wu M F; Roffler S R
CORPORATE SOURCE: Institute of Biomedical Sciences, Academia Sinica, Taipei,
Taiwan.
SOURCE: Bioconjugate chemistry, (2000 Mar-Apr) Vol. 11, No. 2, pp.
258-66.
Journal code: 9010319. ISSN: 1043-1802.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200005
ENTRY DATE: Entered STN: 20000613
Last Updated on STN: 20000613
Entered Medline: 20000531

L2 ANSWER 2 OF 4 MEDLINE on STN
ACCESSION NUMBER: 1998089627 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9428158
TITLE: Immobilization of L-asparaginase into a biocompatible
poly(ethylene glycol)-albumin hydrogel: evaluation of
performance in vivo.
AUTHOR: Jean-Francois J; D'Urso E M; Fortier G
CORPORATE SOURCE: Departement de Chimie-Biochimie, Universite du Quebec,
Montreal, Canada.
SOURCE: Biotechnology and applied biochemistry, (1997 Dec) Vol. 26
(Pt 3), pp. 203-12.
Journal code: 8609465. ISSN: 0885-4513.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199802
ENTRY DATE: Entered STN: 19980217
Last Updated on STN: 20000303
Entered Medline: 19980205

L2 ANSWER 3 OF 4 MEDLINE on STN
ACCESSION NUMBER: 84160696 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6706424
TITLE: Polyethylene glycol reactive antibodies in man: titer
distribution in allergic patients treated with monomethoxy
polyethylene glycol modified allergens or placebo, and in
healthy blood donors.
AUTHOR: Richter A W; Akerblom E
SOURCE: International archives of allergy and applied immunology,
(1984) Vol. 74, No. 1, pp. 36-9.
Journal code: 0404561. ISSN: 0020-5915.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198405
ENTRY DATE: Entered STN: 19900319
Last Updated on STN: 19970203
Entered Medline: 19840522

L2 ANSWER 4 OF 4 MEDLINE on STN
ACCESSION NUMBER: 83107741 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6401699
TITLE: Antibodies against polyethylene glycol produced in animals

by immunization with monomethoxy polyethylene glycol modified proteins.

AUTHOR: Richter A W; Akerblom E

SOURCE: International archives of allergy and applied immunology, (1983) Vol. 70, No. 2, pp. 124-31.
Journal code: 0404561. ISSN: 0020-5915.

PUB. COUNTRY: Switzerland

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198303

ENTRY DATE: Entered STN: 19900318
Last Updated on STN: 19900318
Entered Medline: 19830311

=> d abs 3

L2 ANSWER 3 OF 4 MEDLINE on STN

AB Antibodies to polyethylene glycol (PEG) were analyzed in patients with various allergies and in healthy blood donors employing passive hemagglutination. In untreated allergic patients and in healthy blood donors, naturally occurring anti-PEG antibody titers between 32 and 512 were seen in 3.3 and 0.2%, respectively. During hyposensitization with monomethoxy polyethylene glycol modified ragweed extract and honey bee venom, respectively, the patients showed an anti-PEG antibody response. Titers of 32-512 were found in 50% of the patients directly after the first treatment course. After 2 years of treatment the percentage of patients with such titers declined to 28.5%. Mercaptoethanol treatment of sera indicated that the anti-PEG antibodies predominantly were of the IgM isotype. The weak IgM response found in treated patients is considered to be of no clinical significance.

=> s ABS 2

5100 ABS
3230499 2

L3 42 ABS 2
(ABS(W)2)

=> d abs 12 2

L2 ANSWER 2 OF 4 MEDLINE on STN

AB The L-asparaginase of Escherichia coli (ASNase) is currently used in combination with antineoplastic drugs to treat various lymphoblastic leukaemias. However, its use is limited by severe immunological reactions and the short serum half-life associated with the enzyme. Immobilization of ASNase into a biocompatible matrix can greatly decrease the immunogenicity of the enzyme, increase its half-life in vivo and its therapeutic index. Thus the E. coli ASNase was immobilized in a biocompatible hydrogel made of rat serum albumin and poly(ethylene glycol) (PEG; molecular mass 10 kDa). The effectiveness of this enzymic bioreactor to deplete serum L-asparagine was evaluated after its peritoneal implantation in rats. Seven units of immobilized ASNase/rat depleted serum asparagine to an undetectable level (< 1 microM) during 6 days, while 5 units of immobilized ASNase/rat decreased the level of serum asparagine by 85-90% during at least 2 days. Under both conditions asparagine levels returned to normal about 10 days after surgery, and hydrogels still retained 80% of their enzymic activity when assayed in vitro. After 10-14 days in vivo, hydrogels became opaque and surrounded by a fibrotic capsule with a few inflammatory sites. Nevertheless, the enzymic hydrogel showed great stability in vivo, and, after 4 months of implantation, 12% of the initial ASNase activity was still present. At 6 months, histological analysis showed stabilization of the fibrotic capsule

thickness. Assays on the levels of ASNase and asparagine synthetase indicated an induction of the latter activity, mainly in the pancreas when compared with the level observed in spleen or liver. ELISA tests at 28 days and 120 days showed the presence of anti-ASNase (and, in lower amounts, anti-PEG) antibodies in sera of implanted rats. As observed with other enzyme-immobilization systems used in vivo, the formation of fibroblast-like cell layers around the implant, which block the translocation of the substrate into the enzymic matrix, is the major factor affecting the performance and longevity of the bioreactor.

```
=> s anti () (polyethylene glycol)
      616721 ANTI
        6 ANTIS
      616725 ANTI
        (ANTI OR ANTIS)
      35662 POLYETHYLENE
      5898 POLYETHYLENES
      38703 POLYETHYLENE
        (POLYETHYLENE OR POLYETHYLENES)
      23440 GLYCOL
      28763 GLYCOLS
      41826 GLYCOL
        (GLYCOL OR GLYCOLS)
      23715 POLYETHYLENE GLYCOL
        (POLYETHYLENE(W)GLYCOL)
L4      1 ANTI (W) (POLYETHYLENE GLYCOL)
```

=> d ibib

```
L4  ANSWER 1 OF 1      MEDLINE on STN
ACCESSION NUMBER: 1999278171      MEDLINE
DOCUMENT NUMBER: PubMed ID: 10346886
TITLE: Accelerated clearance of polyethylene glycol-modified
        proteins by anti-polyethylene
        glycol IgM.
AUTHOR: Cheng T L; Wu P Y; Wu M F; Chern J W; Roffler S R
CORPORATE SOURCE: Institute of Biomedical Sciences, Academia Sinica, College
                  of Medicine, National Taiwan University, Taipei, Taiwan.
SOURCE: Bioconjugate chemistry, (1999 May-Jun) Vol. 10, No. 3, pp.
        520-8.
        Journal code: 9010319. ISSN: 1043-1802.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199907
ENTRY DATE: Entered STN: 19990715
            Last Updated on STN: 19990715
            Entered Medline: 19990707
```

```
=> s antibod? (against or to) (peg or (polyethylene glycol))
MISSING OPERATOR 'ANTIBOD? (AGAINST'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
```

```
=> s antibod? (s) (against or to) (s) (peg or (polyethylene glycol))
      708410 ANTIBOD?
      455081 AGAINST
        6 AGAINSTS
      455085 AGAINST
        (AGAINST OR AGAINSTS)
      7985384 TO
        859 TOS
```

```

7985637 TO
      (TO OR TOS)
      9879 PEG
      777 PEGS
      10278 PEG
            (PEG OR PEGS)
      35662 POLYETHYLENE
      5898 POLYETHYLENES
      38703 POLYETHYLENE
            (POLYETHYLENE OR POLYETHYLENES)
      23440 GLYCOL
      28763 GLYCOLS
      41826 GLYCOL
            (GLYCOL OR GLYCOLS)
      23715 POLYETHYLENE GLYCOL
            (POLYETHYLENE(W)GLYCOL)
L5      456 ANTIBOD? (S) (AGAINST OR TO) (S) (PEG OR (POLYETHYLENE GLYCOL))

```

```

=> s clear? or remov?
      358107 CLEAR?
      281667 REMOV?
L6      626149 CLEAR? OR REMOV?

```

```

=> s 16 and 15
L7      68 L6 AND L5

```

```

=> s 17 not py>1999
      3443289 PY>1999
            (PY>19999999)
L8      49 L7 NOT PY>1999

```

```

=> d scan
'DISPLAY SCAN' IS NOT VALID IN CURRENT FILE

```

The DISPLAY SCAN command is not valid in the current file.
Enter HELP FORMATS and HELP DFIELDs to see valid DISPLAY
options in current file.

```

=> d 11

```

```

L1  ANSWER 1 OF 7      MEDLINE on STN
AN  2005175711      MEDLINE
DN  PubMed ID: 15809678
TI  Repeated injections of PEG-PE liposomes generate anti-
    PEG antibodies.
AU  Sroda Kamila; Rydlewski Janusz; Langner Marek; Kozubek Arkadiusz; Grzybek
    Michal; Sikorski Aleksander F
CS  Academic Centre for the Biotechnology of Lipid Aggregates,
    Przybyszewskiego 63/77, 51-148 Wroclaw, Poland.. afsbc@ibmb.uni.wroc.pl
SO  Cellular & molecular biology letters, (2005) Vol. 10, No. 1, pp. 37-47.
    Journal code: 9607427. ISSN: 1425-8153.
CY  Poland
DT  Journal; Article; (JOURNAL ARTICLE)
LA  English
FS  Priority Journals
EM  200508
ED  Entered STN: 20050406
    Last Updated on STN: 20050806
    Entered Medline: 20050805

```

```

=> d 18 1

```

```

L8  ANSWER 1 OF 49      MEDLINE on STN
AN  1999333743      MEDLINE

```

DN PubMed ID: 10403934
 TI Heat treatment of normal human sera reveals antibodies to bactericidal permeability-inducing protein (BPI).
 AU Brownlee A A; Lockwood C M
 CS University of Cambridge, School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK.
 SO Clinical and experimental immunology, (1999 Jul) Vol. 117, No. 1, pp. 183-9.
 Journal code: 0057202. ISSN: 0009-9104.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199907
 ED Entered STN: 19990806
 Last Updated on STN: 19990806
 Entered Medline: 19990728

=> d kwic

L8 ANSWER 1 OF 49 MEDLINE on STN
 AB . . . was maximal at 56 degrees C, with substantial antibody demonstrable after only 5 min at this temperature. In experiments using polyethylene glycol (PEG)6000 to remove immune complexes, the effect of heating could be abrogated by preincubation with 8% PEG, which suggested that these anti BPI antibodies might be complexed in sera. After passage of normal plasma over a protein G column, the acid-eluted fraction contained elevated. . .

=> s antibod? (w) (against or to) (w) (peg or (polyethylene glycol))
 708410 ANTIBOD?
 455081 AGAINST
 6 AGAINSTS
 455085 AGAINST
 (AGAINST OR AGAINSTS)
 7985384 TO
 859 TOS
 7985637 TO
 (TO OR TOS)
 9879 PEG
 777 PEGS
 10278 PEG
 (PEG OR PEGS)
 35662 POLYETHYLENE
 5898 POLYETHYLENES
 38703 POLYETHYLENE
 (POLYETHYLENE OR POLYETHYLENES)
 23440 GLYCOL
 28763 GLYCOLS
 41826 GLYCOL
 (GLYCOL OR GLYCOLS)
 23715 POLYETHYLENE GLYCOL
 (POLYETHYLENE(W)GLYCOL)
 L9 11 ANTIBOD? (W) (AGAINST OR TO) (W) (PEG OR (POLYETHYLENE GLYCOL))

=> s 19 and 16
 L10 0 L9 AND L6

=> s 19 not py>2000
 2953639 PY>2000
 (PY>20009999)
 L11 8 L9 NOT PY>2000

=> d ibib 1-8

L11 ANSWER 1 OF 8 MEDLINE on STN
ACCESSION NUMBER: 1999382152 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10454349
TITLE: Detection and characterization of antibodies
to PEG-IFN-alpha2b using surface plasmon
resonance.
AUTHOR: Takacs M A; Jacobs S J; Bordens R M; Swanson S J
CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ 07033,
USA.
SOURCE: Journal of interferon & cytokine research : the official
journal of the International Society for Interferon and
Cytokine Research, (1999 Jul) Vol. 19, No. 7, pp. 781-9.
Journal code: 9507088. ISSN: 1079-9907.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199910
ENTRY DATE: Entered STN: 19991101
Last Updated on STN: 19991101
Entered Medline: 19991019

L11 ANSWER 2 OF 8 MEDLINE on STN
ACCESSION NUMBER: 97431634 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9287139
TITLE: Immunoliposomes bearing polyethyleneglycol-coupled Fab'
fragment show prolonged circulation time and high
extravasation into targeted solid tumors in vivo.
AUTHOR: Maruyama K; Takahashi N; Tagawa T; Nagaike K; Iwatsuru M
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Teikyo University,
Kanagawa, Japan.. maruyama@pharm.teikyo-u.ac.jp
SOURCE: FEBS letters, (1997 Aug 11) Vol. 413, No. 1, pp. 177-80.
Journal code: 0155157. ISSN: 0014-5793.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199710
ENTRY DATE: Entered STN: 19971224
Last Updated on STN: 19971224
Entered Medline: 19971030

L11 ANSWER 3 OF 8 MEDLINE on STN
ACCESSION NUMBER: 93165399 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8433874
TITLE: Enzyme replacement therapy with polyethylene
glycol-adenosine deaminase in adenosine deaminase
deficiency: overview and case reports of three patients,
including two now receiving gene therapy.
AUTHOR: Hershfield M S; Chaffee S; Sorensen R U
CORPORATE SOURCE: Department of Medicine, Duke University Medical Center,
Durham, North Carolina 27710.
CONTRACT NUMBER: DK20902 (NIDDK)
RR00080 (NCRR)
SOURCE: Pediatric research, (1993 Jan) Vol. 33, No. 1 Suppl, pp.
S42-7; discussion S47-8. Ref: 19
Journal code: 0100714. ISSN: 0031-3998.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English

FILE SEGMENT: Priority Journals
ENTRY MONTH: 199303
ENTRY DATE: Entered STN: 19930402
Last Updated on STN: 19930402
Entered Medline: 19930318

L11 ANSWER 4 OF 8 MEDLINE on STN
ACCESSION NUMBER: 86007216 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2412977
TITLE: Studies on antigenicity of the polyethylene glycol
(PEG)-modified uricase.
AUTHOR: Tsuji J; Hirose K; Kasahara E; Naitoh M; Yamamoto I
SOURCE: International journal of immunopharmacology, (1985) Vol. 7,
No. 5, pp. 725-30.
Journal code: 7904799. ISSN: 0192-0561.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198511
ENTRY DATE: Entered STN: 19900321
Last Updated on STN: 19900321
Entered Medline: 19851121

L11 ANSWER 5 OF 8 MEDLINE on STN
ACCESSION NUMBER: 85156525 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3980111
TITLE: Immune responses to polyethylene glycol modified
L-asparaginase in mice.
AUTHOR: Kawamura K; Igarashi T; Fujii T; Kamisaki Y; Wada H;
Kishimoto S
SOURCE: International archives of allergy and applied immunology,
(1985) Vol. 76, No. 4, pp. 324-30.
Journal code: 0404561. ISSN: 0020-5915.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198505
ENTRY DATE: Entered STN: 19900320
Last Updated on STN: 19900320
Entered Medline: 19850513

L11 ANSWER 6 OF 8 MEDLINE on STN
ACCESSION NUMBER: 84160696 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6706424
TITLE: Polyethylene glycol reactive antibodies in man: titer
distribution in allergic patients treated with monomethoxy
polyethylene glycol modified allergens or placebo, and in
healthy blood donors.
AUTHOR: Richter A W; Akerblom E
SOURCE: International archives of allergy and applied immunology,
(1984) Vol. 74, No. 1, pp. 36-9.
Journal code: 0404561. ISSN: 0020-5915.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198405
ENTRY DATE: Entered STN: 19900319
Last Updated on STN: 19970203
Entered Medline: 19840522

L11 ANSWER 7 OF 8 MEDLINE on STN
ACCESSION NUMBER: 83107741 MEDLINE

DOCUMENT NUMBER: PubMed ID: 6401699
TITLE: Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins.
AUTHOR: Richter A W; Akerblom E
SOURCE: International archives of allergy and applied immunology, (1983) Vol. 70, No. 2, pp. 124-31.
Journal code: 0404561. ISSN: 0020-5915.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198303
ENTRY DATE: Entered STN: 19900318
Last Updated on STN: 19900318
Entered Medline: 19830311

L11 ANSWER 8 OF 8 MEDLINE on STN
ACCESSION NUMBER: 77187848 MEDLINE
DOCUMENT NUMBER: PubMed ID: 16907
TITLE: Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.
AUTHOR: Abuchowski A; McCoy J R; Palczuk N C; van Es T; Davis F F
SOURCE: The Journal of biological chemistry, (1977 Jun 10) Vol. 252, No. 11, pp. 3582-6.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197707
ENTRY DATE: Entered STN: 19900314
Last Updated on STN: 19950206
Entered Medline: 19770723

=> d abs 8

L11 ANSWER 8 OF 8 MEDLINE on STN
AB Methoxypolyethylene glycols of 1900 daltons (PEG-1900) or 5000 daltons (PEG-5000) were covalently attached to bovine liver catalase using 2,4,6-trichloro-s-triazine as the coupling agent. Rabbits were immunized by the intravenous and intramuscular routes with catalase modified by covalent attachment of PEG-1900 to 43% of the amino groups (PEG-1900-catalase). The intravenous antiserum did not yield detectable antibodies against PEG-1900-catalase or native catalase, as determined by Ouchterlony and complement fixation methods, whereas the intramuscular antiserum contained antibodies to both PEG-1900-catalase and catalase. PEG-1900 did not react with either antiserum. Catalase was prepared in which PEG-5000 was attached to 40% of the amino groups (PEG-5000-catalase). This catalase preparation did not react with either antiserum. PEG-1900-catalase retained 93% of its enzymatic activity; PEG-5000-catalase retained 95%. PEG-5000-catalase resisted digestion by trypsin, chymotrypsin, and a protease from *Streptomyces griseus*. PEG-1900-catalase and PEG-5000-catalase exhibited enhanced circulating lives in the blood of acatalasemic mice during repetitive intravenous injections. No evidence was seen of an immune response to injections of the modified enzymes. Mice injected repetitively with PEG-5000-catalase remained immune competent for unmodified catalase, and no evidence of tissue or organ damage was seen.

=> file caplsu
'CAPLSU' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'MEDLINE'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.04

7.25

FILE 'CAPLUS' ENTERED AT 10:54:30 ON 07 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2006 VOL 144 ISS 11

FILE LAST UPDATED: 6 Mar 2006 (20060306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s anti () PEG

398531 ANTI

9 ANTIS

398538 ANTI

(ANTI OR ANTIS)

35011 PEG

1176 PEGS

35503 PEG

(PEG OR PEGS)

L12 10 ANTI (W) PEG

=> s l12 not py>2000

5537520 PY>2000

L13 5 L12 NOT PY>2000

=> d ibib 1-5

L13 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:334699 CAPLUS

TITLE: Bioactive poly(ethylene glycol)-insulin conjugates with enhanced stability and reduced immunogenicity.

AUTHOR(S): Hinds, Ken; Joss, Lisa; Rihova, Blanka; Koh, Jae Joon; Liu, Feng; Baudys, Miroslav; Kim, Sung Wan

CORPORATE SOURCE: Department of Pharmaceutics and Pharmaceutical Chemistry / CCCD, University of Utah, Salt Lake City, UT, 84112, USA

SOURCE: Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, 2000 (2000), POLY-511. American Chemical Society: Washington, D. C. CODEN: 69CLAC

DOCUMENT TYPE: Conference; Meeting Abstract
LANGUAGE: English

L13 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:125916 CAPLUS
DOCUMENT NUMBER: 132:298658
TITLE: Efficient Clearance of Polyethylene glycol-Modified
Immunoenzyme with Anti-PEG
Monoclonal Antibody for Prodrug Cancer Therapy
AUTHOR(S): Cheng, Tian-Lu; Chen, Bing-Mae; Chern, Ji-Wang; Wu,
Ming-Fang; Roffler, Steve R.
CORPORATE SOURCE: Institute of Biomedical Sciences, Academia Sinica,
School of Pharmacy National Taiwan University College
of Medicine, Taipei, Taiwan
SOURCE: Bioconjugate Chemistry (2000), 11(2), 258-266
CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:239090 CAPLUS
DOCUMENT NUMBER: 131:63325
TITLE: Accelerated Clearance of Polyethylene Glycol-Modified
Proteins by Anti-Polyethylene Glycol IgM
AUTHOR(S): Cheng, Tian-Lu; Wu, Pin-Yi; Wu, Ming-Fang; Chern,
Ji-Wang; Roffler, Steve R.
CORPORATE SOURCE: Institute of Biomedical Sciences, Academia Sinica,
Taipei, Taiwan
SOURCE: Bioconjugate Chemistry (1999), 10(3), 520-528
CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:24552 CAPLUS
DOCUMENT NUMBER: 128:162592
TITLE: Immobilization of L-asparaginase into a biocompatible
poly(ethylene glycol)-albumin hydrogel: evaluation of
performance in vivo
AUTHOR(S): Jean-Francois, Jacques; D'urso, Edith Marie; Fortier,
Guy
CORPORATE SOURCE: Laboratoire d'Enzymologie Appliquee, Departement de
Chimie-Biochimie, Universite du Quebec, Montreal,
Montreal, QC, H3C 3P8, Can.
SOURCE: Biotechnology and Applied Biochemistry (1997), 26(3),
203-212
CODEN: BABIEC; ISSN: 0885-4513
PUBLISHER: Portland Press Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:15249 CAPLUS
DOCUMENT NUMBER: 98:15249
TITLE: Antibodies against polyethylene glycol produced in
animals by immunization with monomethoxy polyethylene
glycol-modified proteins

AUTHOR(S): Richter, Ary Wolfgang; Aakerblom, Eva
CORPORATE SOURCE: Dep. Biomed. Res., Pharm. AB, Uppsala, 75104, Swed.
SOURCE: International Archives of Allergy and Applied
Immunology (1983), 70(2), 124-31
CODEN: IAAAAM; ISSN: 0020-5915
DOCUMENT TYPE: Journal
LANGUAGE: English

=> s antibod? (w) (against or to) (w) (peg or (polyethylene glycol))

455631 ANTIBOD?
678912 AGAINST
37 AGAINSTS
678927 AGAINST
(AGAINST OR AGAINSTS)
0 TO
1364 TOS
1364 TO
(TO OR TOS)
35011 PEG
1176 PEGS
35503 PEG
(PEG OR PEGS)
338433 POLYETHYLENE
12590 POLYETHYLENES
342295 POLYETHYLENE
(POLYETHYLENE OR POLYETHYLENES)
344776 GLYCOL
44765 GLYCOLS
360101 GLYCOL
(GLYCOL OR GLYCOLS)
97872 POLYETHYLENE GLYCOL
(POLYETHYLENE(W)GLYCOL)

L14 4 ANTIBOD? (W) (AGAINST OR TO) (W) (PEG OR (POLYETHYLENE GLYCOL))

=> d ibib 1-4

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:191308 CAPLUS
TITLE: Control of hyperuricemia in subjects with refractory
gout, and induction of antibody against poly(ethylene)
glycol (PEG), in a phase I trial of subcutaneous
PEGylated urate oxidase
AUTHOR(S): Ganson, Nancy J.; Kelly, Susan J.; Scarlett, Edna;
Sundy, John S.; Hershfield, Michael S.
CORPORATE SOURCE: Division of Rheumatology, Duke University Medical
Center, Durham, NC, 27710, USA
SOURCE: Arthritis Research & Therapy (2006), 8(1), No pp.
given
CODEN: ARTRCV; ISSN: 1478-6362
URL: <http://arthritis-research.com/content/pdf/ar1861.pdf>
PUBLISHER: BioMed Central Ltd.
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1985:539940 CAPLUS
DOCUMENT NUMBER: 103:139940
TITLE: Studies on antigenicity of the polyethylene glycol
(PEG)-modified uricase
AUTHOR(S): Tsuji, Junichi; Hirose, Katsumi; Kasahara, Etsuko;
Naitoh, Maki; Yamamoto, Itaru
CORPORATE SOURCE: Toyobo Res. Cent., Toyobo Co., Ltd., Ohtsu, 520-02,
Japan

SOURCE: International Journal of Immunopharmacology (1985),
7(5), 725-30
CODEN: IJIMDS; ISSN: 0192-0561
DOCUMENT TYPE: Journal
LANGUAGE: English

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:15249 CAPLUS
DOCUMENT NUMBER: 98:15249
TITLE: Antibodies against
polyethylene glycol produced in
animals by immunization with monomethoxy polyethylene
glycol-modified proteins
AUTHOR(S): Richter, Ary Wolfgang; Aakerblom, Eva
CORPORATE SOURCE: Dep. Biomed. Res., Pharm. AB, Uppsala, 75104, Swed.
SOURCE: International Archives of Allergy and Applied
Immunology (1983), 70(2), 124-31
CODEN: IAAAAM; ISSN: 0020-5915
DOCUMENT TYPE: Journal
LANGUAGE: English

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:449460 CAPLUS
DOCUMENT NUMBER: 87:49460
TITLE: Effect of covalent attachment of polyethylene glycol
on immunogenicity and circulating life of bovine liver
catalase
AUTHOR(S): Abuchowski, Abraham; McCoy, John R.; Palczuk, Nicholas
C.; Van Es, Theo; Davis, Frank F.
CORPORATE SOURCE: Dep. Biochem., Rutgers, State Univ., New Brunswick,
NJ, USA
SOURCE: Journal of Biological Chemistry (1977), 252(11),
3582-6
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English

=> s clear? or remov?
437130 CLEAR?
1200397 REMOV?

L15 1611632 CLEAR? OR REMOV?

=> s l15 and l14
L16 0 L15 AND L14

=> s l14 and retent? or retain?
179765 RETENT?
195985 RETAIN?
L17 195985 L14 AND RETENT? OR RETAIN?

=> s l14 and (retent? or retain?)
179765 RETENT?
195985 RETAIN?
L18 1 L14 AND (RETENT? OR RETAIN?)

=> d ibib

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:449460 CAPLUS
DOCUMENT NUMBER: 87:49460
TITLE: Effect of covalent attachment of polyethylene glycol
on immunogenicity and circulating life of bovine liver
catalase
AUTHOR(S): Abuchowski, Abraham; McCoy, John R.; Palczuk, Nicholas

CORPORATE SOURCE: C.; Van Es, Theo; Davis, Frank F.
Dep. Biochem., Rutgers, State Univ., New Brunswick,
NJ, USA
SOURCE: Journal of Biological Chemistry (1977), 252(11),
3582-6
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d abs kwic

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AB Methoxypolyethylene glycols of 1900 daltons (PEG-1900) or 5000 daltons (PEG-5000) were covalently attached to bovine liver catalase (I) using 2,4,6-trichloro-s-triazine as the coupling agent. Rabbits were immunized i.v. and i.m. with I modified by covalent attachment of PEG-1900 to 43% of the NH₂ groups (PEG-1900-I). The i.v. antiserum had no detectable antibodies against PEG-1900-I or native I, whereas the i.m. antiserum contained antibodies to both PEG-1900-I and I. PEG-1900 did not react with either antiserum. I was prepared in which PEG-5000 was attached to 40% of the NH₂ groups (PEG-5000-I). This I preparation did not react with either antiserum. PEG-1900-I retained 93% of its activity; PEG-5000-I retained 95%. PEG-5000-I resisted digestion by trypsin, chymotrypsin, and a protease from Streptomyces griseus. PEG-1900-I and PEG-5000-I had enhanced circulating lives in the blood of acatalasemic mice during repetitive i.v. injections. No evidence was seen of an immune response to injections of the modified I. Mice injected repetitively with PEG-5000-I remained immune competent for unmodified I, and no evidence of tissue or organ damage was seen.

AB . . . I modified by covalent attachment of PEG-1900 to 43% of the NH₂ groups (PEG-1900-I). The i.v. antiserum had no detectable antibodies against PEG-1900-I or native I, whereas the i.m. antiserum contained antibodies to both PEG-1900-I and I. PEG-1900 did not react with either. . . PEG-5000 was attached to 40% of the NH₂ groups (PEG-5000-I). This I preparation did not react with either antiserum. PEG-1900-I retained 93% of its activity; PEG-5000-I retained 95%. PEG-5000-I resisted digestion by trypsin, chymotrypsin, and a protease from Streptomyces griseus. PEG-1900-I and PEG-5000-I had enhanced circulating lives. . .

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.55	51.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'PCTFULL' ENTERED AT 10:57:26 ON 07 MAR 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 05 MAR 2006 <20060305/UPTX>
MOST RECENT UPDATE WEEK: 200608
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.
USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER
DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION

>>> UPDATING OF BIBLIOGRAPHIC DATA DELAYED DUE TO DELIVERY

FORMAT CHANGES <<<

>>> FULL-TEXT UPDATES CONTINUE. PATENT NUMBER AVAILABLE FOR DISPLAY
ONLY, USE FIELD CODE FPI <<<

>>> SDI SEARCHES (ALERTS) WILL BE RESUMED WHEN BIBLIOGRAPHIC DATA
BECOME AVAILABLE <<<

=> s anti. () PEG
170585 ANTI
169 ANTIS
170619 ANTI
(ANTI OR ANTIS)
35845 PEG
5031 PEGS
38005 PEG
(PEG OR PEGS)

L19 7 ANTI (W) PEG

=> s l19 not py>2000
550224 PY>2000
L20 0 L19 NOT PY>2000

=> s antibod? (w) (against or to) (w) (peg or (polyethylene glycol))
85695 ANTIBOD?
344502 AGAINST
14 AGAINSTS
344503 AGAINST
(AGAINST OR AGAINSTS)
1040820 TO
3118 TOS
1040871 TO
(TO OR TOS)
35845 PEG
5031 PEGS
38005 PEG
(PEG OR PEGS)
132183 POLYETHYLENE
5725 POLYETHYLENES
132985 POLYETHYLENE
(POLYETHYLENE OR POLYETHYLENES)
106336 GLYCOL
41630 GLYCOLS
113363 GLYCOL
(GLYCOL OR GLYCOLS)
67563 POLYETHYLENE GLYCOL
(POLYETHYLENE(W)GLYCOL)
L21 15 ANTIBOD? (W) (AGAINST OR TO) (W) (PEG OR (POLYETHYLENE GLYCOL))

=> s l15 not py>2000
303559 CLEAR?
489065 REMOV?
550224 PY>2000
L22 293482 L15 NOT PY>2000

=> s l21 not py>2000
550224 PY>2000
L23 5 L21 NOT PY>2000

=> d ibib 1-5

L23 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2006017355 PCTFULL
no bibliographic data available - please use FPI for PI information
DESIGNATED STATES

L23 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2000024770 PCTFULL ED 20020515
 TITLE (ENGLISH): DIMERIC THROMBOPOIETIN PEPTIDE MIMETICS BINDING TO MP1
 RECEPTOR AND HAVING THROMBOPOIETIC ACTIVITY
 TITLE (FRENCH): COMPOSES THROMBOPOIETIQUES
 INVENTOR(S): LIU, Chuan-Fa;
 FEIGE, Ulrich;
 CHEETHAM, Janet
 PATENT ASSIGNEE(S): AMGEN INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000024770	A2	20000504

DESIGNATED STATES
 W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
 DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
 KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
 NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM
 AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
 GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML
 MR NE SN TD TG

APPLICATION INFO.: WO 1999-US24834 A 19991022
 PRIORITY INFO.: US 1998-60/105,348 19981023

L23 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1995004159 PCTFULL ED 20020514
 TITLE (ENGLISH): BLOOD LEAD DIAGNOSTIC ASSAY
 TITLE (FRENCH): PROCEDE DIAGNOSTIQUE DE DETERMINATION DE LA PRESENCE DE
 PLOMB DANS LE SANG
 INVENTOR(S): JAFFE, Eileen, K.
 PATENT ASSIGNEE(S): FOX CHASE CANCER CENTER
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9504159	A1	19950209

DESIGNATED STATES
 W:

CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 APPLICATION INFO.: WO 1994-US8626 A 19940802
 PRIORITY INFO.: US 1993-8/100,980 19930803

L23 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1993008838 PCTFULL ED 20020513
 TITLE (ENGLISH): ORAL PHARMACEUTICAL COMPOSITION CONTAINING POLYETHYLENE
 GLYCOL IMMUNOGLOBULIN CONJUGATE
 TITLE (FRENCH): COMPOSITION PHARMACEUTIQUE ORALE CONTENANT UN CONJUGUE
 D'IMMUNOGLOBULINE DE POLYETHYLENE GLYCOL
 INVENTOR(S): CUNNINGHAM-RUNDLES, Charlotte
 PATENT ASSIGNEE(S): MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY
 OF NEW YORK
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9308838	A1	19930513

DESIGNATED STATES
 W:

AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE
 APPLICATION INFO.: WO 1992-US8784 A 19921015
 PRIORITY INFO.: US 1991-7/783,360 19911028

L23 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1993000109 PCTFULL ED 20020513
 TITLE (ENGLISH): METHOD OF STIMULATING IMMUNE RESPONSE USING GROWTH
 HORMONE
 TITLE (FRENCH): PROCEDE DE STIMULATION DE LA REPOSE IMMUNITAIRE A
 L'AIDE D'HORMONE DE CROISSANCE
 INVENTOR(S): CARLSSON, Lena, Mariana, Susann;
 CLARK, Ross, G.;
 CRONIN, Michael, J.;
 JARDIEU, Paula, M.
 PATENT ASSIGNEE(S): GENENTECH, INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9300109	A1	19930107

DESIGNATED STATES

W: AU CA JP AT BE CH DE DK ES FR GB GR IT LU MC NL SE
 APPLICATION INFO.: WO 1992-US4489 A 19920529
 PRIORITY INFO.: US 1991-723,359 19910628

=> d kwic 5

L23 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . antigen did not yield detectable antibodies against P EG-1
 900-catalase or native
 catalase whereas the antiserum from intramuscular administered antigen
 contained antibodies
 to PEG catalase and native catalase. PEG catalase
 did not react with either
 antiserum.

=> d kwic 1-5

L23 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . measured using a sandwich ELISA that utilizes a capture antibody
 to
 aprotinin (produced as described in Example 6) and a reporter
 antibody to PEG (e.g., AGP3 from
 Acadmica Sinica). Aprotinin variant plasma levels may also be measured
 using radiolabeled
 aprotinin variants (e.g., Shin, Pharm. Pharmacol. Commun.. . .

L23 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . In contrast, treatment in the various cycles with PEG-rHuMGDF
 did show
 an inhibition in platelet response by Cycle 4, suggesting that
 antibodies to PEG-
 rHuMGDF have been generated and these anti-MGDF antibodies may be
 i h endogenous rhesus TPO.

L23 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD Polyclonal antibodies to PEGS can be made
 with the purified protein using methods known in the art. Antibodies are
 raised in suitable animals such. . .

L23 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . 42,0 to 79,6 percent of
that found for native IgG,
Example 12
Since in several of the above methods the binding
of a second antibody to PEG-IgG conjugates
to determine
the biologic activities of these conjugates was used to
compare PEG-IgG conjugates to native IgG, experiments
to determine the relative. . .

equal
concentrations (22,5 gg/ml); similar data were found
for other concentrations of IgG tested, 225 gg/ml and
2.25 gg/ml)

TABLE 7

BINDING OF A SECOND ANTIBODY

TO PEG-IgG CONJUGATES

% of Control

IgG Bound % of Control

IgG to ELISA IgG Detected

,Compound Plate* in Solution**

Native IgG 100 100

Conjugates.

L23 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . antigen did not yield detectable antibodies against P EG-1
900-catalase or native
catalase whereas the antiserum from intramuscular administered antigen
contained antibodies
to PEG catalase and native catalase. PEG catalase
did not react with either
antiserum.

=> d his

(FILE 'HOME' ENTERED AT 10:47:25 ON 07 MAR 2006)

FILE 'MEDLINE' ENTERED AT 10:47:38 ON 07 MAR 2006

L1 7 S ANTI () PEG
L2 4 S L1 NOT PY>2000
L3 42 S ABS 2
L4 1 S ANTI () (POLYETHYLENE GLYCOL)
L5 456 S ANTIBOD? (S) (AGAINST OR TO) (S) (PEG OR (POLYETHYLENE GLYCOL
L6 626149 S CLEAR? OR REMOV?
L7 68 S L6 AND L5
L8 49 S L7 NOT PY>1999
L9 11 S ANTIBOD? (W) (AGAINST OR TO) (W) (PEG OR (POLYETHYLENE GLYCOL
L10 0 S L9 AND L6
L11 8 S L9 NOT PY>2000

FILE 'CAPLUS' ENTERED AT 10:54:30 ON 07 MAR 2006

L12 10 S ANTI () PEG
L13 5 S L12 NOT PY>2000
L14 4 S ANTIBOD? (W) (AGAINST OR TO) (W) (PEG OR (POLYETHYLENE GLYCOL
L15 1611632 S CLEAR? OR REMOV?
L16 0 S L15 AND L14
L17 195985 S L14 AND RETENT? OR RETAIN?
L18 1 S L14 AND (RETENT? OR RETAIN?)

FILE 'PCTFULL' ENTERED AT 10:57:26 ON 07 MAR 2006

L19 7 S ANTI () PEG
L20 0 S L19 NOT PY>2000
L21 15 S ANTIBOD? (W) (AGAINST OR TO) (W) (PEG OR (POLYETHYLENE GLYCOL

L22 293482 S L15 NOT PY>2000
L23 5 S L21 NOT PY>2000

=> s clear? or remov?
303559 CLEAR?
489065 REMOV?
L24 578709 CLEAR? OR REMOV?

=> s 124 and 123
L25 5 L24 AND L23

=> d kwic 1-5

L25 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . per molecule, denaturing the
double-stranded DNA, renaturing the DNA to form double-stranded DNA
which can include
sense/antisense pairs from different nicked products, removing
single-stranded portions from

8
reformed duplexes by treatment with S1 nuclease, and ligating the
resulting fragment library into
an expression vector. By this. . .

chain protected peptide may be cleaved with a base and the appropriate
alcohol (e.g., methanol). Side chain protecting groups may be
removed in the usual fashion by
treatment with hydrogen fluoride to obtain the desired ester. In
preparing peptide mimetics
wherein the C-terminall carboxyl. . . dialkylamide (i.e., the
C-terminus is --
C(O)NRR,, where R and R, are alkyl, a lower alkyl). Side chain
protection is then removed in the
usual fashion by treatment with hydrogen fluoride to give the free
amides, alkylamides, or
dialkylamides.

measured using a sandwich ELISA that utilizes a capture antibody to
aprotinin (produced as described in Example 6) and a reporter
antibody to PEG (e.g., AGP3 from
Acadmica Sinica). Aprotinin variant plasma levels may also be measured
using radiolabeled
aprotinin variants (e.g., Shin, Pharm. Pharmacol. Commun.. . .

(80 mg/kg, i.p.) and treated with aprotinin (10 mg/kg, i.v.). Ten
minutes later, the distal 2 mm of tail is removed and placed
in to saline. The time for bleeding to
stop is measured. Aprotinin and active variants reduce the bleeding
time. . .

L25 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD Various studies using animal models (Ulich, TR. et al., Blood 86:971-976
(1995); Hokorn, M.M. et al., Blood 86:4486-4492 (1995)) have
clearly demonstrated
the therapeutic efficacies of TPO and MGDF in bone marrow
transplantation and in
the treatment of thrombocytopenia, a condition that often. . .

Even if the Cys residues that normally form disulfide bonds in the Fe
dimer are

removed or replaced by other residues, the monomeric chains
will generally dimerize
through non-covalent interactions. The term Fe herein is used to. . .

In Fe deletion variants, one or more amino acid residues in an Fe polypeptide are removed. Deletions can be effected at one or both termini of the Fe polypeptide, or with removal of one or more residues within the Fe amino acid sequence. Deletion variants, therefore, include all fragments of an Fe polypeptide. . .

In Fe substitution variants, one or more amino acid residues of an Fe polypeptide are removed and replaced with alternative residues. In one aspect, the substitutions are conservative in nature, however, the invention embraces substitutions that are also. . .

the Fe sequences. In

21

particular, the amino acids at positions 7 and 10 of SEQ ID NO:5 are cysteine residues. One may remove each of these cysteine residues or substitute one or more such cysteine residues with other amino acids, such as Ala or. . .

oil of theobroma. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (I 990, Mack Publishing Co., Easton, PA 18042) pages. . .

incorporated by reference. Such formulations may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the administered agents. Depending on the route of administration, a suitable dose may be calculated according to body weight, body surface. . .

used for side chain protection of the Lys on the linker and Boc-Ile-OH was used for the last coupling. Dde was removed by using anhydrous hydrazine (2% in NMP, 3x2min), followed by coupling with bromoacetic anhydride preformed by the action of DCC. For peptide. . . was effected at RT for 4 hr, using trifluoroacetic acid (TFA) containing 2.5% H₂O, 5% phenol, 2.5% triisopropylsilane and 2.5% thioanisole. After removal of TFA, the cleaved peptide was precipitated with cold anhydrous ether. Disulfide formation of the cyclic peptide was performed directly on the. . .

Clearly, the activity of the tandem linked dimers may also depend on proper selection of the length and composition of the linker. . .

second monomer) and parallel dimers (D terminal of first monomer linked to C terminal of second monomer) in the same assay clearly demonstrated the superiority of tandem dimerized product compared to parallel dimer products. It is interesting to note that a wide range of. . .

protection of the lysine E-amine. Once

the whole peptide chain was assembled, the N-terminal amine was reprotected with t-Boc. Dde was then removed to allow for the bromoacetylation. This strategy gave a high quality crude peptide which was easily purified using conventional reverse phase HPLC.. . .

5 M urea, pH 9. The pH of this mixture was then adjusted to pH 5 with acetic acid. The precipitate was removed by centrifugation and the supernatant was loaded onto a SP-Sepharose Fast Flow column equilibrated in 20 mM NaAc, 100 mM NaCl,. . .

enhance the in vivo activity of the modified peptide by providing it a protection against proteolytic degradation and by slowing down its clearance through renal filtration. It was unexpected that pegylation could further increase the in vitro bioactivity of a tandem dimerized TNIP peptide in.. . .

In contrast, treatment in the various cycles with PEG-rHuMGDF did show an inhibition in platelet response by Cycle 4, suggesting that antibodies to PEG-rHuMGDF have been generated and these anti-MGDF antibodies may be in h endogenous rhesus TPO.

L25 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . the lungs or digestive tract and once ingested, lead accumulates in bones and teeth. Long-term chelation therapy can be used to remove lead from bone tissue. However, if lead poisoning is untreated, the sequestered lead in bone tissue can be reintroduced into.

The present invention includes the step of isolating PEGS from the sample, thereby removing the confounding effect of interfering substances in the sample composition. The use of PEGS as a biological marker is an. . .

and 10⁻⁸ M in hemolysate (P.N.B. Gibbs, A-G. Chaudhry and P.M. Jordan, Biochem. J. 230:25-34 (1985)), PEGS can be quantitatively removed from a hemolysate sample using monoclonal or polyclonal antibodies. PEGS can be isolated from the blood of a test subject using antibodies. . .

Polyclonal antibodies to PEGS can be made with the purified protein using methods known in the art. Antibodies are raised in suitable animals such. . .

PEGS for raising antibodies may be isolated from outdated blood by a method which uses a batch extraction technique to remove the hemoglobin (P.N.B. Gibbs, A-G. Chaudhry and P.M. Jordan, Biochem. J

(b) Lead-inhibited PEGS would be distinguished from active PEGS as follows :

The double dipstick would be removed from the first vessel, split in half, and each individual dipstick, labelled either A or B, would be placed in a. . .

reaction would be allowed to proceed for a short period of time,

approximately five minutes. Alternatively, the dipsticks could be removed to a third vessel containing, respectively, Buffer A plus 10 ALA and Buffer B plus ALA

L25 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . is dissolved in a basic buffer solution, for example 0,01 M sodium phosphate buffer, pH 7,8, and then dialyzed against the buffer to remove residual salts. The concentrated serum Ig is then combined with activated PEG which can be obtained by a chemical process involving either 1,11-carbonyldiimidazole, . . .

serum immunoglobulin G in 0,01 M sodium phosphate buffer at pH 7*8. The resulting solution was then dialyzed against the buffer to remove residual salts. Determination of the final concentration of the immunoglobulin G was done spectrophotometrically using an extinction coefficient of 138 as E45 for. . .

50) to remove residual carbonyldiimidazole, The resulting activated PEG solution was dialyzed against distilled water, lyophilized, and stored desiccated, Example 3

Activated PEG produced by the method. . .

15 g SS-PEG, The mixture is stirred for 30 min at room-temperature and clarified by Millipore filtration (1.2 gm membrane), Unbound SS-PEG is removed by dialysis against 10 volumes of buffer using an Amicon cell as described above, Each preparation of PEG-IgG is sterilized by filtration. . .

Heat aggregated human IgG and PEG-conjugates were produced by heating 10 mg/ml solutions of each in PBS to 630 for 30 minutes, After removing the largest (visible) aggregates by brief centrifugation (3,000 rpm from 5 minutes) the aggregates contained in the supernatants of these solutions were used. . .

42,0 to 79,6 percent of that found for native IgG, Example 12

Since in several of the above methods the binding of a second antibody to PEG-IgG conjugates to determine the biologic activities of these conjugates was used to compare PEG-IgG conjugates to native IgG, experiments to determine the relative. . .

buffer, pH 4,5 with pepsin (Worthington Biochemical Corp,, Free Hold, NJ,) at an enzyme substrate ratio of 1:100, In one experiment, aliquots were removed from the reaction mixture at 1, 3f 5l 7f 9 and 16 hours; in another, all reactions were stopped in 6 hours,. . .

equal concentrations (22,5 gg/ml); similar data were found for other concentrations of IgG tested, 225 gg/ml and 2.25 ggfml)

TABLE 7

BINDING OF A SECOND ANTIBODY

TO PEG-IgG CONJUGATES
% of Control
IgG Bound % of Control
IgG to ELISA IgG Detected
,Compound Plate* in Solution**
Native IgG 100 100
Conjugates.

L25 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . tolerate. The short half-life of hGH is believed to be due to its small molecular weight (22,000 dalton), and rapid renal clearance, which has been found to be proportional to the molecular weight of protein in circulation. Pegylation, meaning conjugating polyethylene glycol. . . .

. . . bovine serum albumin exhibited a blood circulating life in rabbits similar to native bovine serum albumin go except that it was not removed from circulation by the eventual development of antibodies.

. . . antigen did not yield detectable antibodies against PEG-1 900-catalase or native catalase whereas the antiserum from intramuscular administered antigen contained antibodies to PEG catalase and native catalase. PEG catalase did not react with either antiserum.

. . . attached polymers such as polyethylene glycol, polypropylene glycol or carbohydrates; and 3) other macromolecules such as proteins, lipids, or glycolipids that reduce clearance and are not immunogenic.

. . . the continuous presence of GH when the GH is complexed with itself or with another macromolecule such that the GH is not cleared from the plasma. Intermittent GH use is defined as administration every 3 or more days, preferably every 6 or more days.. . .

The present invention clearly shows that the s.c. administration of hGH as a continuous infusion or PEG-GH as daily or infrequent intermittent injections are optimal. . . .

Therefore, it is clear that at this dose of hGH (0.1 mg/kg/day) continuous administration and daily injection have equal effects on whole body weight gain.. . .

. . . and that the difference could be due to the GHBP giving a 10 more continuous GH exposure and a larger response. Clearly the rate of weight gain for hGH plus GHBP is substantially greater. This increased spleen weight gain is also plotted as. . . .

. . . growth of the thymus. This large absolute and relative growth response may be due to the met-hGH delivered by injections being cleared rapidly from the body whereas the PEG-hGH molecules are cleared more slowly and leads to a

relative continuous GH exposure.

At sacrifice, a blood sample was taken, and the liver, kidneys, heart, spleen, and thymus were removed, blotted dry, and immediately weighed. The spleen and thymus were immediately placed in buffer and then cells were obtained by.

treated rats gained 34.5 ± 9.4 g, and IGF and GH-treated rats gained 45.5

9.9 g. The response to IGR was clearly large, and the response to GH plus IGR appeared to be additive. IGR at the doses used was markedly anabolic. A.

The effect of IGR was clearly greater than that of hGH.

There was a clear effect of IGR on all the organ weights.

Liver increased by 6.6%, kidneys by 16.6%, heart by 18.5%, thymus by 27.0%,.

30 Using this scheme characteristic, thymic involution was seen in the excipient and the GH-treated groups. However, there was clear evidence of lymphocytic hyperplasia and the restoration of the thymic architecture in the groups that received des-IGF-I and des-IGF-I plus bGH. The.

blood sample was taken, and the thymus, spleen, heart, liver, kidney, and mandibular and mesenteric lymph nodes from each treatment group were removed aseptically and weighed.

growth of the spleen and the thymus after 7 days of treatment with IGF-I. In the first experiment there was a clear dose-related effect of IGR on the spleen (excipient 105 ± 14 ; low dose 124 ± 21 ; medium dose 145 ± 58 ; experiment; this was probably due to the thymus being dissected differently by different dissectors. In the repeat experiment, one dissector uniformly removed the thymus, and significant thymic growth was detected (excipient, 15.2 ± 1.3 ; high dose 26.2 ± 6.4 mg, $p = 0.006$).

Femurs and tibias were removed from 40 donor animals. The bone marrow was flushed out with PBS. Cells were centrifuged and washed with saline. Viable.

at this time. The remaining animals were sacrificed 23 days after the irradiation treatment. Spleens, thymuses, livers, and hearts were removed and weighed. Long bones were taken for histology and the spleens and thymuses retained for cytological and in vitro assays. Blood was.

92.0 ± 8.3

IGF-I high $27.3 \pm 10.9^*$ $51.2 \pm 9.3^{**}$ $125.0 \pm 35.4^*$ 103.6 ± 19.4

$p < 0.05$ of Marrow Only on same day

$p < 0.01$

15

There was a clear effect of IGR increasing thymus and spleen

weight in this model.

The body weight changes for all four groups are shown in Figure 21. The figure shows

clearly the very large weight loss in the animals following radiation exposure. There was a

clear dose-related effect of IGR protecting the mice from this catabolism. High-dose IGR had a significant anabolic effect as early as seven. . .

is as an immunoadjuvant. Whenever immunizing a mammal or avian, priming with GH and or IGR to accelerate the immunization process is clearly indicated in the present invention.

CLMEN. . . of claim 1 wherein said method is accomplished using a growth hormone complexed to one or more macromolecules to reduce GH clearance from the blood plasma.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	17.97	69.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

STN INTERNATIONAL LOGOFF AT 11:04:45 ON 07 MAR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS	4	DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS	5	DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER

NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
 NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
 IPC reform
 NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
 USPAT2
 NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUIDB, and IFICDB
 NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
 INPADOC
 NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
 NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
 NEWS 13 JAN 30 Saved answer limit increased
 NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
 added to TULSA
 NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
 visualization results
 NEWS 16 FEB 22 Status of current WO (PCT) information on STN
 NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN
 NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added
 NEWS 19 FEB 27 New STN AnaVist pricing effective March 1, 2006
 NEWS 20 FEB 28 MEDLINE/LMEDLINE reload improves functionality
 NEWS 21 FEB 28 TOXCENTER reloaded with enhancements
 NEWS 22 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral
 property data
 NEWS 23 MAR 01 INSPEC reloaded and enhanced
 NEWS 24 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
 CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
 V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:23:29 ON 07 MAR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:23:41 ON 07 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3

DICTIONARY FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s CLPGHWGFPSC/SQEP
      1 CLPGHWGFPSC/SQEP
      86624 SQL=11
L1      1 CLPGHWGFPSC/SQEP
        (CLPGHWGFPSC/SQEP AND SQL=11)
```

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	7.49	7.70

FILE 'CAPLUS' ENTERED AT 11:24:11 ON 07 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 6 Mar 2006 (20060306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s l1
L2      2 L1
```

=> d ibib 1-2

L2 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:754239 CAPLUS
DOCUMENT NUMBER: 137:284340
TITLE: Liposome targeting of matrix metalloproteinase inhibitors
INVENTOR(S): Penate Medina, Oula; Koivunen, Erkki; Kinnunen, Paavo
PATENT ASSIGNEE(S): Licentia Ltd., Finland
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076491	A1	20021003	WO 2002-FI252	20020326
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
FI 2001000620	A	20020927	FI 2001-620	20010326
FI 113840	B1	20040630		
CA 2441227	AA	20021003	CA 2002-2441227	20020326
EE 200300467	A	20031215	EE 2003-467	20020326
EP 1372694	A1	20040102	EP 2002-706813	20020326
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002008681	A	20040330	BR 2002-8681	20020326
CN 1531439	A	20040922	CN 2002-807311	20020326
JP 2004529127	T2	20040924	JP 2002-575004	20020326
NZ 528043	A	20050826	NZ 2002-528043	20020326
US 2004213833	A1	20041028	US 2003-471980	20030916
NO 2003004280	A	20031125	NO 2003-4280	20030925
US 2005271588	A1	20051208	US 2005-125186	20050510
PRIORITY APPLN. INFO.:			FI 2001-620	A 20010326
			WO 2002-FI252	W 20020326
			US 2003-471980	A3 20030916
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:401931 CAPLUS
DOCUMENT NUMBER: 135:247122
TITLE: Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro
AUTHOR(S): Medina, Oula Penate; Soderlund, Tim; Laakkonen, Liisa J.; Tuominen, Esa K. J.; Koivunen, Erkki; Kinnunen, Paavo K. J.
CORPORATE SOURCE: Helsinki Biophysics and Biomembrane Group, Department of Medical Chemistry, Institute of Biomedicine, University of Helsinki, Helsinki, FIN-00014, Finland
SOURCE: Cancer Research (2001), 61(10), 3978-3985
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal

LANGUAGE: English
REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	3.20	10.90

FILE 'REGISTRY' ENTERED AT 11:25:08 ON 07 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3
DICTIONARY FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s CLPGHWGFPPSC/SQSP
L3 26 CLPGHWGFPPSC/SQSP

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	28.89	39.79

FILE 'CAPLUS' ENTERED AT 11:25:31 ON 07 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 6 Mar 2006 (20060306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 21 L3

=> s 14 and liposom?

49407 LIPOSOM?

L5 2 L4 AND LIPOSOM?

=> d ibib 1-5

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:754239 CAPLUS

DOCUMENT NUMBER: 137:284340

TITLE: Liposome targeting of matrix metalloproteinase inhibitors

INVENTOR(S): Penate Medina, Oula; Koivunen, Erkki; Kinnunen, Paavo

PATENT ASSIGNEE(S): Licentia Ltd., Finland

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076491	A1	20021003	WO 2002-FI252	20020326
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
FI 2001000620	A	20020927	FI 2001-620	20010326
FI 113840	B1	20040630		
CA 2441227	AA	20021003	CA 2002-2441227	20020326
EE 200300467	A	20031215	EE 2003-467	20020326
EP 1372694	A1	20040102	EP 2002-706813	20020326
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
BR 2002008681	A	20040330	BR 2002-8681	20020326
CN 1531439	A	20040922	CN 2002-807311	20020326
JP 2004529127	T2	20040924	JP 2002-575004	20020326
NZ 528043	A	20050826	NZ 2002-528043	20020326
US 2004213833	A1	20041028	US 2003-471980	20030916
NO 2003004280	A	20031125	NO 2003-4280	20030925
US 2005271588	A1	20051208	US 2005-125186	20050510
PRIORITY APPLN. INFO.:			FI 2001-620	A 20010326
			WO 2002-FI252	W 20020326

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:401931 CAPLUS
 DOCUMENT NUMBER: 135:247122
 TITLE: Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro
 AUTHOR(S): Medina, Oula Penate; Soderlund, Tim; Laakkonen, Liisa J.; Tuominen, Esa K. J.; Koivunen, Erkki; Kinnunen, Paavo K. J.
 CORPORATE SOURCE: Helsinki Biophysics and Biomembrane Group, Department of Medical Chemistry, Institute of Biomedicine, University of Helsinki, Helsinki, FIN-00014, Finland
 SOURCE: Cancer Research (2001), 61(10), 3978-3985
 CODEN: CNREA8; ISSN: 0008-5472
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s target?

L6 460128 TARGET?

=> s l6 and l4

L7 7 L6 AND L4

=> s l7 not py>2000

5537520 PY>2000

L8 0 L7 NOT PY>2000

=> s l7 not py>2001

4594403 PY>2001

L9 1 L7 NOT PY>2001

=> d l7 ibib 1-7

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:979013 CAPLUS
 DOCUMENT NUMBER: 142:18193
 TITLE: The status, quality, and expansion of the NIH full-length cDNA project: The mammalian gene collection (MGC)
 AUTHOR(S): Gerhard, Daniela S.; Wagner, Lukas; Feingold, Elise A.; Shenmen, Carolyn M.; Grouse, Lynette H.; Schuler, Greg; Klein, Steven L.; Old, Susan; Rasooly, Rebekah; Good, Peter; Guyer, Mark; Peck, Allicon M.; Derge, Jeffery G.; Lipman, David; Collins, Francis S.
 CORPORATE SOURCE: The MGC Project Team, NIH, USA
 SOURCE: Genome Research (2004), 14(10b), 2121-2127
 CODEN: GEREFS; ISSN: 1088-9051
 PUBLISHER: Cold Spring Harbor Laboratory Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:471053 CAPLUS
 DOCUMENT NUMBER: 141:37227
 TITLE: Gene expression profiles for detecting soft tissue sarcomas and compositions and methods of screening for soft tissue sarcoma modulators

INVENTOR(S): Aziz, Natasha; Ginsburg, Wendy M.; Zlotnik, Albert
 PATENT ASSIGNEE(S): Protein Design Labs, Inc., USA
 SOURCE: PCT Int. Appl., 210 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048938	A2	20040610	WO 2003-US38193	20031126
WO 2004048938	A3	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004253606	A1	20041216	US 2003-723860	20031126
PRIORITY APPLN. INFO.:			US 2002-429739P	P 20021126

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:449883 CAPLUS
 DOCUMENT NUMBER: 140:402911
 TITLE: Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
 INVENTOR(S): Nevins, Joseph R.; West, Mike; Huang, Andrew T.
 PATENT ASSIGNEE(S): Duke University, USA
 SOURCE: PCT Int. Appl., 886 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038376	A2	20040506	WO 2003-XA33946	20031024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004038376	A2	20040506	WO 2003-US33946	20031024
WO 2004038376	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: US 2002-420729P P 20021024
 US 2002-421062P P 20021025
 US 2002-421102P P 20021025
 US 2002-424701P P 20021108
 US 2002-424715P P 20021108
 US 2002-424718P P 20021108
 US 2002-425256P P 20021112
 US 2003-448461P P 20030221
 US 2003-448462P P 20030221
 US 2003-457877P P 20030327
 US 2003-458373P P 20030331
 WO 2003-US33946 A 20031024

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:837371 CAPLUS
 DOCUMENT NUMBER: 139:333132
 TITLE: Targets for therapeutic intervention
 identified in the human mitochondrial proteome
 INVENTOR(S): Ghosh, Soumitra S.; Fahy, Eoin D.; Zhang, Bing;
 Gibson, Bradford W.; Taylor, Steven W.; Glenn, Gary
 M.; Warnock, Dale E.
 PATENT ASSIGNEE(S): Mitokor, USA; The Buck Institute for Age Research
 SOURCE: PCT Int. Appl., 180 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087768	A2	20031023	WO 2003-US10870	20030404
WO 2003087768	A3	20051124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2004101874 A1 20040527 US 2003-408765 20030404 PRIORITY APPLN. INFO.: US 2002-372843P P 20020412 US 2002-389987P P 20020617 US 2002-412418P P 20020920				

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:754239 CAPLUS
 DOCUMENT NUMBER: 137:284340
 TITLE: Liposome targeting of matrix
 metalloproteinase inhibitors
 INVENTOR(S): Penate Medina, Oula; Koivunen, Erkki; Kinnunen, Paavo
 PATENT ASSIGNEE(S): Licentia Ltd., Finland
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002076491 A1 20021003 WO 2002-FI252 20020326
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 FI 2001000620 A 20020927 FI 2001-620 20010326
 FI 113840 B1 20040630
 CA 2441227 AA 20021003 CA 2002-2441227 20020326
 EE 200300467 A 20031215 EE 2003-467 20020326
 EP 1372694 A1 20040102 EP 2002-706813 20020326
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2002008681 A 20040330 BR 2002-8681 20020326
 CN 1531439 A 20040922 CN 2002-807311 20020326
 JP 2004529127 T2 20040924 JP 2002-575004 20020326
 NZ 528043 A 20050826 NZ 2002-528043 20020326
 US 2004213833 A1 20041028 US 2003-471980 20030916
 NO 2003004280 A 20031125 NO 2003-4280 20030925
 US 2005271588 A1 20051208 US 2005-125186 20050510
 PRIORITY APPLN. INFO.: FI 2001-620 A 20010326
 WO 2002-FI252 W 20020326
 US 2003-471980 A3 20030916
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:401931 CAPLUS
 DOCUMENT NUMBER: 135:247122
 TITLE: Binding of novel peptide inhibitors of type IV
 collagenases to phospholipid membranes and use in
 liposome targeting to tumor cells in vitro
 AUTHOR(S): Medina, Oula Penate; Soderlund, Tim; Laakkonen, Liisa
 J.; Tuominen, Esa K. J.; Koivunen, Erkki; Kinnunen,
 Paaavo K. J.
 CORPORATE SOURCE: Helsinki Biophysics and Biomembrane Group, Department
 of Medical Chemistry, Institute of Biomedicine,
 University of Helsinki, Helsinki, FIN-00014, Finland
 SOURCE: Cancer Research (2001), 61(10), 3978-3985
 CODEN: CNREA8; ISSN: 0008-5472
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:265589 CAPLUS
 DOCUMENT NUMBER: 134:309238
 TITLE: Human genes which expression is responsive to shear
 stress, the cDNA and protein sequences, and their use
 for developing drugs for vascular diseases
 INVENTOR(S): Nojima, Hiroshi; Yoshisue, Hajime; Obayashi, Masaya;
 Ota, Toshio; Kawabata, Ayako; Sakurada, Kazuhiro;
 Kuga, Tetsuro; Sekine, Susumu; Nakamura, Yusuke;
 Sugano, Sumio
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 678 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025427	A1	20010412	WO 2000-JP6840	20001002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000074523	A5	20010510	AU 2000-74523	20001002
EP 1225224	A1	20020724	EP 2000-963041	20001002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			JP 1999-280976	A 19991001
			WO 2000-JP6840	W 20001002
REFERENCE COUNT:	16	THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> file pctfull
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
19.90	59.69

FILE 'PCTFULL' ENTERED AT 11:27:46 ON 07 MAR 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 05 MAR 2006 <20060305/UPTX>
MOST RECENT UPDATE WEEK: 200608
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.
USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION

>>> UPDATING OF BIBLIOGRAPHIC DATA DELAYED DUE TO DELIVERY
FORMAT CHANGES <<<

>>> FULL-TEXT UPDATES CONTINUE. PATENT NUMBER AVAILABLE FOR DISPLAY
ONLY, USE FIELD CODE FPI <<<

>>> SDI SEARCHES (ALERTS) WILL BE RESUMED WHEN BIBLIOGRAPHIC DATA
BECOME AVAILABLE <<<

=> s CLPGHWGFPC
L10 1 CLPGHWGFPC

=> s ?CLPGHWGFPC?
L11 1 ?CLPGHWGFPC?

=> d ibib

L11 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002076491 PCTFULL ED 20021011 EW 200240
TITLE (ENGLISH): LIPOSOME TARGETING OF MATRIX METALLOPROTEINASE
INHIBITORS
TITLE (FRENCH): CIBLAGE DE LIPOSOMES AU MOYEN D'INHIBITEURS DE

INVENTOR(S): METALLOPROTEINASES MATRICIELLES
PENATE MEDINA, Oula, Sturenkatu 13 A 31, FIN-00510
Helsinki, FI [FI, FI];
KOIVUNEN, Erkki, Lokkisaarentie 5 C 319, FIN-00980
Helsinki, FI [FI, FI];
KINNUNEN, Paavo, Punarinnantie 4, FIN-02660 Espoo, FI
[FI, FI]
PATENT ASSIGNEE(S): LICENTIA LTD, Erottajankatu 19 B 5, FIN-00130 Helsinki,
FI [FI, FI], for all designates States except US;
PENATE MEDINA, Oula, Sturenkatu 13 A 31, FIN-00510
Helsinki, FI [FI, FI], for US only;
KOIVUNEN, Erkki, Lokkisaarentie 5 C 319, FIN-00980
Helsinki, FI [FI, FI], for US only;
KINNUNEN, Paavo, Punarinnantie 4, FIN-02660 Espoo, FI
[FI, FI], for US only
AGENT: OY JALO ANT-WUORINEN AB\$, Iso Roobertinkatu 4-6 A,
FIN-00120 Helsinki\$, FI
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002076491	A1	20021003

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-FI252 A 20020326
PRIORITY INFO.: FI 2001-20010620 20010326

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.13	62.82

STN INTERNATIONAL LOGOFF AT 11:28:42 ON 07 MAR 2006